Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Rodbard

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
JAMA Internal Medicine|December 6, 2017
Concerns About Conclusions of Self-monitoring of Blood GlucoseAugusto Pimazoni-Netto, David Rodbard
Diabetes Technology & Therapeutics|December 17, 2009
Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injectionsDavid Rodbard, Lois Jovanovic, Satish K Garg
Diabetes Technology & Therapeutics|February 1, 2021
Insulin Metrics: Need for Development of Consensus Standards for Reporting of Insulin Dosing DataHoward Wolpert, William H Polonsky, David Rodbard
Pediatric Endocrinology Reviews : PER|September 30, 2010
Assessing glycemic variation: why, when and how?Fergus J Cameron, Peter A Baghurst, David Rodbard
Journal of Diabetes Science and Technology|December 7, 2010
The minimum frequency of glucose measurements from which glycemic variation can be consistently assessedPeter A Baghurst, David Rodbard, Fergus J Cameron
Diabetes Technology & Therapeutics|July 15, 2011
Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy-a randomized controlled trialAugusto Pimazoni-Netto, David Rodbard, Maria Teresa Zanella, et al.
Diabetes, Obesity & Metabolism|February 11, 2025
Characterizing insulin dosing behaviour and glycaemic excursions: Development of metrics using connected insulin pen and continuous glucose monitoringHoward Wolpert, David Rodbard, Jie Xue, et al.
Diabetes Technology & Therapeutics|April 18, 2020
Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and OpportunitiesSatish K Garg, David Rodbard, Irl B Hirsch, et al.
Diabetes Technology & Therapeutics|March 26, 2026
Quality-Score (Q-Score) Can Be More Sensitive than %Time in Range and Several Other CGM Metrics in Detecting Responses to Therapeutic InterventionsDavid Rodbard, Petra Augstein, Peter Heinke, et al.
Journal of the Endocrine Society|April 10, 2023
Proof-of-concept Application of Continuous Glucose Monitoring Data Analytics to Identify Diabetes GlucotypesDevin W Steenkamp, Michael C Cheney, Zhihui Ju, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
JAMA Internal Medicine|December 6, 2017
Concerns About Conclusions of Self-monitoring of Blood GlucoseAugusto Pimazoni-Netto, David Rodbard
Diabetes Technology & Therapeutics|December 17, 2009
Responses to continuous glucose monitoring in subjects with type 1 diabetes using continuous subcutaneous insulin infusion or multiple daily injectionsDavid Rodbard, Lois Jovanovic, Satish K Garg
Diabetes Technology & Therapeutics|February 1, 2021
Insulin Metrics: Need for Development of Consensus Standards for Reporting of Insulin Dosing DataHoward Wolpert, William H Polonsky, David Rodbard
Pediatric Endocrinology Reviews : PER|September 30, 2010
Assessing glycemic variation: why, when and how?Fergus J Cameron, Peter A Baghurst, David Rodbard
Journal of Diabetes Science and Technology|December 7, 2010
The minimum frequency of glucose measurements from which glycemic variation can be consistently assessedPeter A Baghurst, David Rodbard, Fergus J Cameron
Diabetes Technology & Therapeutics|July 15, 2011
Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy-a randomized controlled trialAugusto Pimazoni-Netto, David Rodbard, Maria Teresa Zanella, et al.
Diabetes, Obesity & Metabolism|February 11, 2025
Characterizing insulin dosing behaviour and glycaemic excursions: Development of metrics using connected insulin pen and continuous glucose monitoringHoward Wolpert, David Rodbard, Jie Xue, et al.
Diabetes Technology & Therapeutics|April 18, 2020
Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and OpportunitiesSatish K Garg, David Rodbard, Irl B Hirsch, et al.
Diabetes Technology & Therapeutics|March 26, 2026
Quality-Score (Q-Score) Can Be More Sensitive than %Time in Range and Several Other CGM Metrics in Detecting Responses to Therapeutic InterventionsDavid Rodbard, Petra Augstein, Peter Heinke, et al.
Journal of the Endocrine Society|April 10, 2023
Proof-of-concept Application of Continuous Glucose Monitoring Data Analytics to Identify Diabetes GlucotypesDevin W Steenkamp, Michael C Cheney, Zhihui Ju, et al.
Pageof 6